But if you've already been diagnosed with prostate cancer, you may need a different test-- for the prostate-specific membrane antigen or PSMA. PSA can show up in cells throughout the body ...

The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

One-month online access to a database for therapeutics and therapy candidates targeting PSMA (prerequisite: access to internet). In addition to androgen deprivation therapy (ADT), there have been ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...